These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 16035941)
21. Anti-Tax antibody levels in asymptomatic carriers, oligosymptomatic carriers, patients with rheumatologic disease or with HAM/TSP do not correlate with HTLV-1 proviral load. de Souza JG; da Fonseca FG; Martins ML; Martins CP; de Carvalho LD; Coelho-dos-Reis JG; Carneiro-Proietti AB; Martins-Filho OA; Barbosa-Stancioli EF; J Clin Virol; 2011 Jan; 50(1):13-8. PubMed ID: 20951636 [TBL] [Abstract][Full Text] [Related]
22. Pathological mechanisms of human T-cell lymphotropic virus type I-associated myelopathy (HAM/TSP). Osame M J Neurovirol; 2002 Oct; 8(5):359-64. PubMed ID: 12402162 [TBL] [Abstract][Full Text] [Related]
23. Human T-cell lymphotropic virus type I and neurological diseases. Nagai M; Osame M J Neurovirol; 2003 Apr; 9(2):228-35. PubMed ID: 12707853 [TBL] [Abstract][Full Text] [Related]
24. Human T cell lymphotropic virus type 1 (HTLV-1) proviral load of HTLV-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients according to new diagnostic criteria of HAM/TSP. Grassi MF; Olavarria VN; Kruschewsky Rde A; Mascarenhas RE; Dourado I; Correia LC; de Castro-Costa CM; Galvão-Castro B J Med Virol; 2011 Jul; 83(7):1269-74. PubMed ID: 21567429 [TBL] [Abstract][Full Text] [Related]
27. Induction of CD4+, human T lymphotropic virus type-1-specific cytotoxic T lymphocytes from patients with HAM/TSP. Recognition of an immunogenic region of the gp46 envelope glycoprotein of human T lymphotropic virus type-1. Jacobson S; Reuben JS; Streilein RD; Palker TJ J Immunol; 1991 Feb; 146(4):1155-62. PubMed ID: 1704032 [TBL] [Abstract][Full Text] [Related]
28. Pathogenesis of chronic progressive myelopathy associated with human T-cell lymphotropic virus type I. Höllsberg P Acta Neurol Scand Suppl; 1997; 169():86-93. PubMed ID: 9174644 [TBL] [Abstract][Full Text] [Related]
29. Target epitopes of HTLV-1 recognized by class I MHC-restricted cytotoxic T lymphocytes in patients with myelopathy and spastic paraparesis and infected patients with autoimmune disorders. Kozako T; Akimoto M; Toji S; White Y; Suzuki S; Arima T; Suruga Y; Matsushita K; Shimeno H; Soeda S; Kubota R; Izumo S; Uozumi K; Arima N J Med Virol; 2011 Mar; 83(3):501-9. PubMed ID: 21264872 [TBL] [Abstract][Full Text] [Related]
31. Human T-lymphotropic virus type 1 (HTLV-1) and regulatory T cells in HTLV-1-associated neuroinflammatory disease. Araya N; Sato T; Yagishita N; Ando H; Utsunomiya A; Jacobson S; Yamano Y Viruses; 2011 Sep; 3(9):1532-48. PubMed ID: 21994794 [TBL] [Abstract][Full Text] [Related]
32. Human T cell lymphotropic virus type I (HTLV-I) p12I is dispensable for HTLV-I transmission and maintenance of infection in vivo. Furukawa Y; Usuku K; Izumo S; Osame M AIDS Res Hum Retroviruses; 2004 Oct; 20(10):1092-9. PubMed ID: 15585100 [TBL] [Abstract][Full Text] [Related]
33. Leukotrienes are upregulated and associated with human T-lymphotropic virus type 1 (HTLV-1)-associated neuroinflammatory disease. Trindade BC; Sorgi CA; Nicolete LD; Malta TM; Pinto MT; Takayanagui OM; Covas DT; Martins Filho OA; Kashima S; Faccioli LH PLoS One; 2012; 7(12):e51873. PubMed ID: 23284797 [TBL] [Abstract][Full Text] [Related]
34. Genetic control and dynamics of the cellular immune response to the human T-cell leukaemia virus, HTLV-I. Bangham CR; Hall SE; Jeffery KJ; Vine AM; Witkover A; Nowak MA; Wodarz D; Usuku K; Osame M Philos Trans R Soc Lond B Biol Sci; 1999 Apr; 354(1384):691-700. PubMed ID: 10365395 [TBL] [Abstract][Full Text] [Related]
35. Impaired function of human T-lymphotropic virus type 1 (HTLV-1)-specific CD8+ T cells in HTLV-1-associated neurologic disease. Sabouri AH; Usuku K; Hayashi D; Izumo S; Ohara Y; Osame M; Saito M Blood; 2008 Sep; 112(6):2411-20. PubMed ID: 18502825 [TBL] [Abstract][Full Text] [Related]
36. Novel insights into human T-lymphotropic virus type-1 (HTLV-1) pathogenesis-host interactions in the manifestation of HTLV-1-associated myelopathy/tropical spastic paraparesis. Ahmadi Ghezeldasht S; Mosavat A; Rezaee SA Rev Med Virol; 2024 Jul; 34(4):e2567. PubMed ID: 38937135 [TBL] [Abstract][Full Text] [Related]
37. How does HTLV-I persist despite a strong cell-mediated immune response? Asquith B; Bangham CR Trends Immunol; 2008 Jan; 29(1):4-11. PubMed ID: 18042431 [TBL] [Abstract][Full Text] [Related]
38. Reduced Tim-3 expression on human T-lymphotropic virus type I (HTLV-I) Tax-specific cytotoxic T lymphocytes in HTLV-I infection. Abdelbary NH; Abdullah HM; Matsuzaki T; Hayashi D; Tanaka Y; Takashima H; Izumo S; Kubota R J Infect Dis; 2011 Apr; 203(7):948-59. PubMed ID: 21402546 [TBL] [Abstract][Full Text] [Related]
39. Neuronal molecular mimicry in immune-mediated neurologic disease. Levin MC; Krichavsky M; Berk J; Foley S; Rosenfeld M; Dalmau J; Chang G; Posner JB; Jacobson S Ann Neurol; 1998 Jul; 44(1):87-98. PubMed ID: 9667596 [TBL] [Abstract][Full Text] [Related]
40. Human T cell leukemia virus type I-induced disease: pathways to cancer and neurodegeneration. Barmak K; Harhaj E; Grant C; Alefantis T; Wigdahl B Virology; 2003 Mar; 308(1):1-12. PubMed ID: 12706085 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]